Chemotherapy with Irinotecan (CPT-11), a Topoisomerase-I Inhibitor, for Refractory and Relapsed Non-Hodgkin's Lymphoma

References

• Harris N. L., Jaffe E., Stein Banks P. M., Chan J. K., Cleary M. L., Delsol G., De Wolf-Peeters C., Falini B., Gatter K. C. A Revised European-American Classification of Lymphoid Neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392
   PubMed Web of Science ®Google Scholar
• The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A Predictive Model for Aggressive Non-Hodgkin's Lymphoma. The New England Journal of Medicine 1993; 329: 987–994
   Google Scholar
• Fisher R. I., Gaynor E. R., Dahlberg S., Oken M. M., Grogan T. M., Mize E. M., Glick J. H., Coltman C. A., Jr., Miller T. P. Comparison of a Standard Regimen (CHOP) With Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's Lymphoma. The New England Journal of Medicine 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• Gianni A. M., Bregni M., Siena S., Brambilla C., Di Nicola M., Lombardi F., Gandola L., Tarella C., Pileri A., Ravagnani F., Valagussa P., Bonadonna G., Stern A. C., Magni M., Caracciolo D. High-Dose Chemotherapy and Autologous Bone Marrow Transplantation Compared with MACOP-B in Aggressive B-Cell Lymphoma. The New England Journal of Medicine 1997; 336: 1290–1297
   PubMed Web of Science ®Google Scholar
• Miller T. P., Dahlberg S., Cassady J. R., Adelstein D. J., Spier C. M., Grogan T. M., Le Blanc M., Carlin S., Chase E., Fisher R. I. Chemotherapy Alone Compared With Chemotherapy Plus Radiotherapy for Localized Intermediate- and High-Grade Non-Hodgkin's Lymphoma. The New England Journal of Medicine 1998; 339: 21–26
   PubMed Web of Science ®Google Scholar
• Wilson H., Bryant G., Bates S., Fojo A., Wittes R. E., Steinberg S. M., Kohler D. R., Jaffe E. S., Herdt J., Cheson B. D. EPOCH Chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. Journal of Clinical Oncology 1993; 11: 1573–1582
   PubMed Web of Science ®Google Scholar
• Velasquez W. S., McLaughlin P., Tucker S., Hagemeister F. B., Swan F., Rodriguez M. A., Romaguera J., Rubenstein E., Cabanillas F. ESHAP–an Effective Chemotherapy Regimen in Refractory and Relapsing Lymphoma: a 4-year follow-up study. Journal of Clinical Oncology 1994; 12: 1169–1176
   PubMed Web of Science ®Google Scholar
• Rodriguez M. A., Cabanillas F. C., Velasquez W., Hagemeister F. B., McLaughlin P., Swan F., Romaguera J. E. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. Journal of Clinical Oncology 1995; 13: 1734–1741
   PubMed Web of Science ®Google Scholar
• Philip T., Guglielmi C., Hagenbeek A., Somers R., Van der Lelie H., Bron D., Sonneveld P., Gisselbrecht C., Cahn J. Y., Harousseau J. L. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. New England Journal of Medicine 1995; 333: 1540–1545
   PubMed Web of Science ®Google Scholar
• Stiff Dahlberg P. J. S., Forman S. J., McCall A. R., Horning S. J., Nademanee A. P., Blume K. G., Le Blanc M., Fisher R. I. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens: A Southwest Oncology Group Trial. Journal of Clinical Oncology 1998; 16: 48–55
   PubMed Web of Science ®Google Scholar
• Frewin R., Turner D., Tighe M., Davies S., Rule S., Johnson S. Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders. The British Journal of Haematology 1999; 104(3)612–613
   PubMed Web of Science ®Google Scholar
• McLaughlin P., Grillo-Lopez A. J., Link B. K., Levy R., Czuczman M. S., Williams M. E., Heyman M. R., Bence-Bruckler I., White C. A., Cabanillas F., Jain V., Ho A. D., Lister J., Wey K., Shen D., Dallaire B. K. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology 1998; 16: 2825–2833
   PubMed Web of Science ®Google Scholar
• Saotome T., Takagi T., Sakai C., Kumagai K., Tamaru J. Combination chemotherapy with irinotecan and Adriamycin for refractory and relapsed non-Hodgkin's lymphoma. Annals of Oncology 2000; 11: 115–116
   PubMed Web of Science ®Google Scholar
• Rothenberg M. L. Topoisomerase I inhibitors: review and update. Annals of Oncology 1997; 8: 837–855
   PubMed Web of Science ®Google Scholar
• Tanizawa A., Fujimori A., Fujimori Y., Pommier Y. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. Journal of National Cancer Institute 1994; 86: 836–842
   PubMed Web of Science ®Google Scholar
• Abigerges D., Armand J. P., Chabot G. G., Da Costa L., Fadel E., Cote C., Herait P., Gandia D. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. Journal of National Cancer Institute 1994; 86: 446–449
   PubMed Web of Science ®Google Scholar
• Rothenberg M. L., Kuhn J. G., Burris H. A., 3rd, Nelson J., Eckardt J. R., Tristan-Morales M., Hilsenbeck S. G., Weiss G. R., Smith L. S., Rodriguez G. I. Phase I and pharmacokinetic trial of weekly CPT-11. Journal of Clinical Oncology 1993; 11: 2194–2204
   PubMed Web of Science ®Google Scholar
• Taguchi T., Wakui A., Hasegawa K., Niitani H., Furue H., Ohta K., Hattori T. Phase I clinical study of CPT-11. Gan To Kagaku Ryoho 1990; 17: 115–120
   PubMedGoogle Scholar
• Fukuoka M., Negoro S., Niitani H., Furue H., Hasegawa K., Hara Y., Hara N., Taguchi T. A phase I study of weekly administration of CPT-11 in lung cancer. Gan To Kagaku Ryoho 1990; 17: 993–997
   PubMedGoogle Scholar
• Chabot G. G., Abigerges D., Catimel G., Culine S., De Forni M., Extra J. M., Mahjoubi M., Herait P., Armand J. P., Bugat R., Clavel M., Marty M. E. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Annals of Oncology 1995; 6: 141–151
   PubMed Web of Science ®Google Scholar
• Ohe Y., Sasaki Y., Shinkai T., Eguchi K., Tamura T., Kojima A., Kunikane H., Okamoto H., Karato A., Ohmatsu H., Kanzawa F., Saijo N. Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. Journal of National Cancer Institute 1992; 84: 972–974
   PubMed Web of Science ®Google Scholar
• Ota K., Ohno R., Shirakawa S., Masaoka T., Okada K., Ohashi Y., Taguchi T. Late phase II clinical study of irinotecan hydrochloride (CPT-11) in the treatment of malignant lymphoma and acute leukemia. Gan To Kagaku Ryoho 1994; 21: 1047–1055
   PubMedGoogle Scholar
• Society of Japanese Pharmacopoeia (ed.). Summary Basis of Approval (SBA) No. 1Revised edition. Yakuji Nippo, ltd., Tokyo 1996; 123
   Google Scholar
• Kunimoto T., Nitta K., Tanaka T., Uehara N., Baba H., Takeuchi M., Yokokura T., Sawada S., Miyasaka T., Mutai M. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Research 1987; 47: 5944–5947
   PubMed Web of Science ®Google Scholar
• Tsuruo T., Matsuzaki T., Matsushita M., Saito H., Yokokura T. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemotherpy and Pharmacology 1988; 21: 71–74
   PubMed Web of Science ®Google Scholar
• Furuta T., Yokokura T. Effect of administration schedules on the antitumor activity of CPT-11, a camptothecin derivative. Gan To Kagaku Ryoho 1990; 17: 121–130
   PubMedGoogle Scholar
• Kano Y., Suzuki K., Akutsu M., Suda K., Inoue Y., Yoshida M., Sakamoto S., Miura Y. Effects of CPT-11 in combination with other anti-cancer agents in culture. International Journal of Cancer 1992; 50: 604–610
   PubMed Web of Science ®Google Scholar
• Akutsu M., Suzuki K., Tsunoda S., Kano Y., Miura Y. Effect of SN-38 in combination with other anticancer agents against Daudi cells. Gan To Kagaku Ryoho 1994; 21: 607–611
   Google Scholar
• Oguro M., Seki Y. Combination cancer chemotherapy using a DNA topoisomerase inhibitor CPT-11, as a core agent: The in vitro evaluation. Gan To Kagaku Ryoho 1991; 18: 1556–1561
   PubMedGoogle Scholar
• Ohno R., Okada K., Masaoka T., Kuramoto A., Arima T., Yoshida Y., Ariyoshi H., Ichimaru M., Sakai Y., Oguro M., Ito Y, Morishima Y., Yokomaku S., Ota K. An early phase II study of CPT-11, a new derivative of camptothecin, for the treatment of leukemia and lymphoma. Journal of Clinical Oncology 1990; 8: 1907–1912
   PubMed Web of Science ®Google Scholar
• Tsuda H., Takatsuki K., Ohno R., Masaoka T., Okada K., Shirakawa S., Ohashi Y, Ohta K., Taguchi T. And the CPT-11 study group on hematological malignancy. abstract. Proceedings of American Sociaty of Clinical Oncology 1992; 11: 316
   Google Scholar
• Tsuda H., Takatsuki K., Ohno R., Masaoka T., Okada K., Shirakawa S., Ohashi Y., Ota K. Treatment of adult T-cell leukaemia-lymphoma with irinotecan hydrochloride (CPT-11). British Journal of Cancer 1994; 70: 771–774
   PubMed Web of Science ®Google Scholar
• Makino T., Nakahara K., Takatsuka Y., Shimotakahara S., Utsunomiya A., Hanada S., Tokunaga M., Arima T. Successful treatment of chemotherapy-resistant adult T cell leukemia/lymphoma by irinotecan hydrochloride (CPT-11). Rinsho Ketsueki 1994; 35: 42–48
   PubMedGoogle Scholar
• Yamauchi T., Amaya N., Yoshio N., Yoshida A., Tsutani H., Ueda T. Successful salvage treatment with irinotecan (CPT-11) of recurrent malignant lymphoma in an aged patient, and CPT-11 pharmacokinetics. International Journal of Hematology 1999; 69: 165–169
   PubMed Web of Science ®Google Scholar
• Tsutani H., Inai K., Kishi S., Morinaga K., Naiki H., Ueda T. Hepatic tumor rupture following effectual treatment with irinotecan in a patient with highly refractory malignant lymphoma. 1996. International Journal of Hematology 1996; 70: 178–180
   Google Scholar
• Tobinai K., Hotta T., Saito H., Ohnishi K., Ohno R., Ogura M., Ariyoshi Y., Takeyama K., Kobayashi T., Ohashi Y., Shirakawa S. Combination phase I/II study of irinotecan hydrochloride (CPT-11) and carboplatin in relapsed or refractory non-Hodgkin's lymphoma. Japanese Journal of Clinical Oncology 1996; 26: 455–60
   PubMed Web of Science ®Google Scholar
• Ohtsu T., Sasaki Y., Igarashi T., Murayama T., Kobayashi Y., Tobinai K. Unexpected hepatotoxicities in patients with non-Hodgkin's lymphoma treated with irinotecan (CPT-11) and etoposide. Japanese Journal of Clinical Oncology 1998; 28: 502–506
   PubMed Web of Science ®Google Scholar
• Sakai C., Saotome T., Takeshita A., Nakaseko C., Kumagai K., Takagi T. Improvement of quality of life (QOL) and life prolongation by CPT-11+adriamycin (ADM) therapy: report of 4 cases of non-Hodgkin's lymphoma refractory to conventional chemotherapies. Gan To Kagaku Ryoho 1999; 26: 1999, 709–714
   PubMedGoogle Scholar
• Ise M., Sakai C., Tsujimura H., Kumagai K., Takenouchi T., Takagi T. Successful treatment with CPT-11 and Adriamycin for hemophagocytic syndrome associated with intravascular lymphomatosis. Rinsho Ketsueki 1998; 39: 1131–1136
   PubMedGoogle Scholar
• Boku N, Ohtsu A, Shimada Y, Shirao K, Seki S, Saito H, Sakata Y, Hyodo I. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. Journal of Clinical Oncology 1999; 17: 319–323
   PubMed Web of Science ®Google Scholar
• De Vore R F, Johnson D H, Crawford J, Garst J, Dimery I W, Eckardt J, Eckhardt S G, Elfring G L, Schaaf L J, Hanover C K, Miller LL. Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology 1999; 17: 2710–2720
   PubMed Web of Science ®Google Scholar
• Sugiyama T, Yakushiji M, Noda K, Ikeda M, Kudoh R, Yajima A, Tomoda Y, Terashima Y, Takeuchi S, Hiura M, Saji F, Takahashi T, Umesaki N, Sato S, Hatae M, Ohashi Y. Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer. Oncology 2000; 58: 31–37
   PubMed Web of Science ®Google Scholar